A retrospective analysis of malnutrition risk, nutritional support and outcomes in COVID-19 patients.
COVID-19
Malnutrition
Nutritional assessment
Nutritional supplementation
Outcomes
Journal
Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
10
01
2022
revised:
09
04
2022
accepted:
18
05
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
27
7
2022
Statut:
ppublish
Résumé
The association between obesity and disease severity in COVID-19 has been reported, whilst the impact of undernutrition remains less well-defined. Here we describe nutritional risk profiles of consecutive COVID-19 hospital inpatients, together with clinical outcomes and the impact of nutritional therapy. This was a retrospective case-control study of adult inpatients admitted to University College London Hospital between February and July 2020 with PCR-confirmed SARS-CoV-2. Data were extracted from electronic health records and compared to a control group of consecutive patients admitted between March and April 2019. COVID-19 patients were classified as at low, moderate or high nutritional risk according to a local nutritional screening tool on admission. Data relating to demographics, nutritional therapy and clinical outcomes were collected and compared between nutritional risk groups. A significantly higher proportion of the COVID-19 group were found to be at high nutritional risk (132/381, 34.6% vs. 105/468, 22.4%; p < 0.0001). Within the COVID-19 group, multivariate analysis showed that those at moderate and high nutritional risk had increased odds of having an above-average peak CRP (p = 0.004) and a below-average nadir albumin (p = 0.0002). Inpatient length of stay was on average 5.8 days longer for COVID-19 patients at moderate and high nutritional risk compared to those at low nutritional risk (p = 0.0008). COVID-19 patients at moderate nutritional risk on admission had a higher proportion of ICU admissions (28/89, 31.5% vs. 32/160, 20.0%; p = 0.01). Mortality was significantly worse in COVID-19 patients at high nutritional risk compared to those at low nutritional risk (52/132, 39.4% vs. 24/160, 15.0%; p < 0.0001). Prescription of enteral nutrition in ward-based COVID-19 patients at high nutritional risk was associated with lower inpatient mortality (20/67, 29.9% vs. 22/38, 57.9%; p = 0.009). In crude analysis, the 30-day mortality rate post-discharge was higher in those at moderate and high nutritional risk compared to those at low nutritional risk (13/151, 8.6% vs. 4/136, 2.9%, p < 0.05). Amongst patients at high nutritional risk, nutritional therapy was less common amongst non-white patients compared to white patients (12/29, 41.4% vs. 46/66, 70.0%; p = 0.006). Patients admitted with COVID-19 were at significant risk of undernutrition, which was associated with adverse clinical outcomes in our study. This risk was reduced by simple nutritional interventions. Mortality amongst patients at high nutritional risk persisted beyond discharge, suggesting close nutritional follow up in the period following hospital admission is warranted.
Sections du résumé
BACKGROUND
The association between obesity and disease severity in COVID-19 has been reported, whilst the impact of undernutrition remains less well-defined. Here we describe nutritional risk profiles of consecutive COVID-19 hospital inpatients, together with clinical outcomes and the impact of nutritional therapy.
METHODS
This was a retrospective case-control study of adult inpatients admitted to University College London Hospital between February and July 2020 with PCR-confirmed SARS-CoV-2. Data were extracted from electronic health records and compared to a control group of consecutive patients admitted between March and April 2019. COVID-19 patients were classified as at low, moderate or high nutritional risk according to a local nutritional screening tool on admission. Data relating to demographics, nutritional therapy and clinical outcomes were collected and compared between nutritional risk groups.
RESULTS
A significantly higher proportion of the COVID-19 group were found to be at high nutritional risk (132/381, 34.6% vs. 105/468, 22.4%; p < 0.0001). Within the COVID-19 group, multivariate analysis showed that those at moderate and high nutritional risk had increased odds of having an above-average peak CRP (p = 0.004) and a below-average nadir albumin (p = 0.0002). Inpatient length of stay was on average 5.8 days longer for COVID-19 patients at moderate and high nutritional risk compared to those at low nutritional risk (p = 0.0008). COVID-19 patients at moderate nutritional risk on admission had a higher proportion of ICU admissions (28/89, 31.5% vs. 32/160, 20.0%; p = 0.01). Mortality was significantly worse in COVID-19 patients at high nutritional risk compared to those at low nutritional risk (52/132, 39.4% vs. 24/160, 15.0%; p < 0.0001). Prescription of enteral nutrition in ward-based COVID-19 patients at high nutritional risk was associated with lower inpatient mortality (20/67, 29.9% vs. 22/38, 57.9%; p = 0.009). In crude analysis, the 30-day mortality rate post-discharge was higher in those at moderate and high nutritional risk compared to those at low nutritional risk (13/151, 8.6% vs. 4/136, 2.9%, p < 0.05). Amongst patients at high nutritional risk, nutritional therapy was less common amongst non-white patients compared to white patients (12/29, 41.4% vs. 46/66, 70.0%; p = 0.006).
CONCLUSION
Patients admitted with COVID-19 were at significant risk of undernutrition, which was associated with adverse clinical outcomes in our study. This risk was reduced by simple nutritional interventions. Mortality amongst patients at high nutritional risk persisted beyond discharge, suggesting close nutritional follow up in the period following hospital admission is warranted.
Identifiants
pubmed: 35871924
pii: S2405-4577(22)00282-0
doi: 10.1016/j.clnesp.2022.05.017
pmc: PMC9135638
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
196-206Informations de copyright
Copyright © 2022 European Society for Clinical Nutrition and Metabolism. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest No author has declared a conflict of interest.
Références
Crit Care Med. 2017 Feb;45(2):156-163
pubmed: 28098623
F1000Res. 2021 Jan 21;10:40
pubmed: 33824716
Nutrition. 2021 Feb;82:111048
pubmed: 33277149
Clin Nutr. 2018 Feb;37(1):336-353
pubmed: 28802519
Crit Rev Immunol. 2012;32(1):23-63
pubmed: 22428854
Arch Dis Child. 1986 Feb;61(2):182-5
pubmed: 3082298
EBioMedicine. 2020 Nov;61:103026
pubmed: 33039714
Clin Nutr ESPEN. 2021 Oct;45:381-388
pubmed: 34620344
Clin Nutr. 2018 Aug;37(4):1121-1132
pubmed: 28927897
Br J Nutr. 2021 Nov 14;126(9):1296-1303
pubmed: 33342449
Trends Immunol. 2016 Jun;37(6):386-398
pubmed: 27237815
J Nutr. 1998 Feb;128(2):166-74
pubmed: 9446838
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
J Nutr Health Aging. 2021;25(3):369-373
pubmed: 33575730
Crit Care Med. 2015 Dec;43(12):2605-15
pubmed: 26427592
Clin Med (Lond). 2020 Apr 27;:
pubmed: 32341077
Clin Nutr. 2019 Feb;38(1):48-79
pubmed: 30348463
Drugs Context. 2014 Jul 31;3:212265
pubmed: 25126097
Thorax. 2021 Sep;76(9):907-919
pubmed: 33579777
Adv Nutr. 2014 Nov 14;5(6):702-11
pubmed: 25398733
Am J Clin Nutr. 1986 Oct;44(4):449-52
pubmed: 3094357
JPEN J Parenter Enteral Nutr. 2021 Jan;45(1):32-42
pubmed: 32613660
Clin Nutr. 2020 Jun;39(6):1631-1638
pubmed: 32305181